Ha habido 50 transacciones internas recientes registradas para Verona Pharma plc (VRNA), incluyendo 15 compras y 34 ventas. El total de compras internas fue valorado en $431.64K y el total de ventas internas en $39.14M.
Internos destacados con actividad reciente incluyen Fisher Andrew, Hahn Mark W, Zaccardelli David. Las transacciones internas pueden proporcionar información sobre cómo la dirección de la empresa ve la valoración y perspectivas futuras de la acción.
Operaciones de Insiders — VRNA
| Fecha |
Nombre |
Cargo |
Tipo de Transacción |
Acciones |
Precio Promedio |
Valor |
Acciones en Propiedad |
| 2025-06-16 |
Fisher Andrew |
General Counsel |
Venta Informativa |
80,000 |
$11.53 |
$922K |
359,999 |
| 2025-06-11 |
Hahn Mark W |
Chief Financial Officer |
Venta Informativa |
400,000 |
$11.40 |
$4.56M |
12,278,992 |
| 2025-06-11 |
Zaccardelli David |
President and CEO |
Venta Informativa |
400,000 |
$11.40 |
$4.56M |
13,190,168 |
| 2025-05-29 |
Hahn Mark W |
Chief Financial Officer |
Venta Informativa |
204,864 |
$9.33 |
$1.91M |
12,678,992 |
| 2025-05-29 |
Zaccardelli David |
President and CEO |
Venta Informativa |
208,696 |
$9.33 |
$1.95M |
13,590,168 |
| 2025-05-28 |
Hahn Mark W |
Chief Financial Officer |
Venta Informativa |
162,704 |
$9.30 |
$1.51M |
12,883,856 |
| 2025-05-28 |
Zaccardelli David |
President and CEO |
Venta Informativa |
157,704 |
$9.30 |
$1.47M |
13,798,864 |
| 2025-05-27 |
Hahn Mark W |
Chief Financial Officer |
Venta Informativa |
32,432 |
$9.53 |
$308.98K |
13,046,560 |
| 2025-05-27 |
Zaccardelli David |
President and CEO |
Venta Informativa |
33,600 |
$9.53 |
$320.18K |
13,956,568 |
| 2025-05-20 |
Sinha Vikas |
Director |
Ejercicio de Opciones (Venta) |
160,000 |
$0.50 |
$80.61K |
384 |
| 2025-05-15 |
Fisher Andrew |
General Counsel |
Venta Informativa |
80,000 |
$8.57 |
$685.6K |
359,999 |
| 2025-05-15 |
Fisher Andrew |
General Counsel |
Ejercicio de Opciones |
80,000 |
$2.01 |
$160.9K |
439,999 |
| 2025-05-14 |
Ackermann Christina |
Director |
Venta Informativa |
40,000 |
$8.44 |
$337.6K |
41,880 |
| 2025-05-06 |
Rickard Kathleen A. |
Chief Medical Officer |
Venta Informativa |
114,984 |
$8.82 |
$1.01M |
2,546,472 |
| 2025-05-02 |
Hahn Mark W |
Chief Financial Officer |
Venta Informativa |
400,000 |
$9.09 |
$3.64M |
13,078,992 |
| 2025-05-02 |
Zaccardelli David |
President and CEO |
Venta Informativa |
400,000 |
$9.09 |
$3.64M |
13,990,168 |
| 2025-05-01 |
Ebsworth David R |
Director |
Ejercicio de Opciones |
140,000 |
$1.93 |
$270.73K |
- |
| 2025-05-01 |
Hahn Mark W |
Chief Financial Officer |
Ejercicio de Opciones (Venta) |
200,000 |
- |
- |
1,000,000 |
| 2025-05-01 |
Zaccardelli David |
President and CEO |
Ejercicio de Opciones (Venta) |
200,000 |
- |
- |
1,000,000 |
| 2025-05-01 |
Rickard Kathleen A. |
Chief Medical Officer |
Ejercicio de Opciones (Venta) |
50,000 |
- |
- |
250,000 |
| 2025-04-29 |
Sinha Vikas |
Director |
Venta Informativa |
4,952 |
$8.92 |
$44.18K |
74,440 |
| 2025-04-29 |
Hahn Mark W |
Chief Financial Officer |
Ejercicio de Opciones (Venta) |
229,512 |
- |
- |
445,488 |
| 2025-04-29 |
Zaccardelli David |
President and CEO |
Ejercicio de Opciones (Venta) |
229,512 |
- |
- |
445,488 |
| 2025-04-29 |
Rickard Kathleen A. |
Chief Medical Officer |
Ejercicio de Opciones (Venta) |
86,064 |
- |
- |
167,056 |
| 2025-04-29 |
Fisher Andrew |
General Counsel |
Ejercicio de Opciones (Venta) |
86,064 |
- |
- |
167,056 |
| 2025-04-29 |
Sinha Vikas |
Director |
Ejercicio de Opciones (Venta) |
120,384 |
$1.70 |
$204.65K |
- |
| 2025-04-25 |
Ebsworth David R |
Director |
Concesión de RSU |
96,000 |
- |
- |
96,000 |
| 2025-04-25 |
Shah Mahendra |
Director |
Concesión de RSU |
96,000 |
- |
- |
96,000 |
| 2025-04-25 |
Sinha Vikas |
Director |
Concesión de RSU |
96,000 |
- |
- |
96,000 |
| 2025-04-25 |
Edwards Martin |
Director |
Concesión de RSU |
96,000 |
- |
- |
96,000 |
| 2025-04-25 |
Ackermann Christina |
Director |
Concesión de RSU |
96,000 |
- |
- |
96,000 |
| 2025-04-25 |
Ullman Anders |
Director |
Concesión de RSU |
96,000 |
- |
- |
96,000 |
| 2025-04-25 |
Cunningham Kenneth |
Director |
Concesión de RSU |
96,000 |
- |
- |
96,000 |
| 2025-04-25 |
Deschamps Lisa |
Director |
Concesión de RSU |
96,000 |
- |
- |
96,000 |
| 2025-04-25 |
Brady James Aloysius |
Director |
Concesión de RSU |
96,000 |
- |
- |
96,000 |
| 2025-04-25 |
Austwick Michael |
Director |
Concesión de RSU |
96,000 |
- |
- |
96,000 |
| 2025-03-19 |
Fisher Andrew |
General Counsel |
Donación (Recibida) |
1 |
- |
- |
300,001 |
| 2025-03-12 |
Rickard Kathleen A. |
Chief Medical Officer |
Venta Informativa |
79,264 |
$8.35 |
$661.94K |
2,608,976 |
| 2025-02-26 |
Ebsworth David R |
Director |
Ejercicio de Opciones (Venta) |
96,000 |
$2.67 |
$256.32K |
- |
| 2025-02-03 |
Hahn Mark W |
Chief Financial Officer |
Retención Fiscal de RSU |
166,888 |
$7.16 |
$1.2M |
13,326,848 |
| 2025-02-03 |
Zaccardelli David |
President and CEO |
Retención Fiscal de RSU |
166,728 |
$7.16 |
$1.19M |
14,238,024 |
| 2025-02-03 |
Rickard Kathleen A. |
Chief Medical Officer |
Retención Fiscal de RSU |
33,240 |
$7.16 |
$238.08K |
2,688,240 |
| 2025-02-01 |
Hahn Mark W |
Chief Financial Officer |
Concesión de RSU |
200,000 |
- |
- |
13,493,736 |
| 2025-02-01 |
Zaccardelli David |
President and CEO |
Concesión de RSU |
200,000 |
- |
- |
14,404,752 |
| 2025-02-01 |
Rickard Kathleen A. |
Chief Medical Officer |
Concesión de RSU |
50,000 |
- |
- |
2,721,480 |
| 2024-12-06 |
Hahn Mark W |
Chief Financial Officer |
Venta Informativa |
183,728 |
$5.01 |
$920.31K |
13,293,736 |
| 2024-12-06 |
Zaccardelli David |
President and CEO |
Venta Informativa |
162,800 |
$5.01 |
$815.4K |
14,204,752 |
| 2024-12-05 |
Hahn Mark W |
Chief Financial Officer |
Venta Informativa |
640,048 |
$5.01 |
$3.2M |
13,477,464 |
| 2024-12-05 |
Zaccardelli David |
President and CEO |
Venta Informativa |
640,264 |
$5.01 |
$3.21M |
14,367,552 |
| 2024-12-04 |
Hahn Mark W |
Chief Financial Officer |
Venta Informativa |
58,184 |
$5.00 |
$291K |
14,117,512 |
■ Informativa — transacción en mercado abierto (más significativa)
■ No informativa (compra) — premio, ejercicio de opción, conversión
■ No informativa (venta) — retención fiscal, venta de adjudicación
■ Neutral — regalo, fideicomiso, vencimiento
